Irinotecan Plus Low-Dose Cisplatin for à-Fetoprotein-Producing Gastric Carcinoma with Multiple Liver Metastases: Report of Two Cases
Surgery Today2002Vol. 32(12), pp. 1075–1080
Citations Over TimeTop 20% of 2002 papers
Shinya Shimada, Naoko Hayashi, Takashi Marutsuka, Yoshifumi Baba, Sachio Yokoyama, Ken-ichi Iyama, Michio Ogawa
Related Papers
- → Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial(2010)52 cited
- → UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan(2009)34 cited
- → Irinotecan and colorectal cancer: the role of p53, VEGF-C and α-B-crystallin expression(2009)14 cited
- → Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients(2001)56 cited
- → Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.(2015)